These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mode of action and in-vitro activity of vancomycin. Watanakunakorn C J Antimicrob Chemother; 1984 Dec; 14 Suppl D():7-18. PubMed ID: 6440886 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Matzke GR; McGory RW; Halstenson CE; Keane WF Antimicrob Agents Chemother; 1984 Apr; 25(4):433-7. PubMed ID: 6732213 [TBL] [Abstract][Full Text] [Related]
4. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ducharme MP; Slaughter RL; Edwards DJ Ther Drug Monit; 1994 Oct; 16(5):513-8. PubMed ID: 7846752 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Moellering RC; Krogstad DJ; Greenblatt DJ Rev Infect Dis; 1981; 3 suppl():S230-5. PubMed ID: 7342286 [TBL] [Abstract][Full Text] [Related]
10. On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari. Hammes WP; Neuhaus FC Antimicrob Agents Chemother; 1974 Dec; 6(6):722-8. PubMed ID: 4451345 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Matzke GR; Kovarik JM; Rybak MJ; Boike SC Clin Pharm; 1985; 4(3):311-5. PubMed ID: 4006395 [TBL] [Abstract][Full Text] [Related]
12. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Barth RH; DeVincenzo N Kidney Int; 1996 Sep; 50(3):929-36. PubMed ID: 8872968 [TBL] [Abstract][Full Text] [Related]
14. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Blouin RA; Bauer LA; Miller DD; Record KE; Griffen WO Antimicrob Agents Chemother; 1982 Apr; 21(4):575-80. PubMed ID: 7081978 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Rotschafer JC; Crossley K; Zaske DE; Mead K; Sawchuk RJ; Solem LD Antimicrob Agents Chemother; 1982 Sep; 22(3):391-4. PubMed ID: 7137982 [TBL] [Abstract][Full Text] [Related]
16. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Healy DP; Polk RE; Garson ML; Rock DT; Comstock TJ Antimicrob Agents Chemother; 1987 Mar; 31(3):393-7. PubMed ID: 3579256 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of vancomycin in Japanese adult patients. Yasuhara M; Iga T; Zenda H; Okumura K; Oguma T; Yano Y; Hori R Ther Drug Monit; 1998 Apr; 20(2):139-48. PubMed ID: 9558127 [TBL] [Abstract][Full Text] [Related]
18. Case analysis of hepatotoxicity caused by vancomycin. Wu J; Zhou Y J Med Case Rep; 2024 Jun; 18(1):267. PubMed ID: 38831463 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and preclinical evaluation of novel Spoelstra GB; Blok SN; Reali Nazario L; Noord L; Fu Y; Simeth NA; IJpma FFA; van Oosten M; van Dijl JM; Feringa BL; Szymanski W; Elsinga PH Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2583-2596. PubMed ID: 38644432 [TBL] [Abstract][Full Text] [Related]